Balance of 2011 very positive for the Ciocca, with 2,300 new and 330 patients treated in clinical trials.
Care and research data center consolidate it as reference oncology unit at national and international levels.
– The volume of patients seen in the CIOCCA in 2011 has increased 22 percent over the previous year, which meets the objectives set for the year just ended, and is now comparable to that of the major public hospitals the Community of Madrid
– Patients treated and the latest technologies, with the best diagnostic and therapeutic methods, which are made available to allow the CIOCCA multidisciplinary and personalized medicine class
– The director of CIOCCA described as “spectacular” the percentage of patients treated in clinical trials, 15 percent of the total (one third of the latter in Phase I)
– Next to the Hospital Vall d’Hebron (Barcelona), the CIOCCA is a center of reference and research at European level in Phase I and is the only one of the Community of Madrid with a consolidated program of experimental therapy
– For 2012 the CIOCCA includes the objective of serving 2,500 patients and treated 400 new clinical trials, 20 percent more this year
– Unit of Hematology and Oncology attended in 2011 to 168 new patients and 1574 review consultations and 833 administered chemotherapy treatments. Hospital admissions totaled 433, with an average stay of 4.78 days, and treatments at the Day Hospital to 902
– The actuarial survival of cancer patients treated in the service is more than 81%, according to the National Registry of Childhood Tumours of Spain
Madrid, January 2012 .- Comprehensive Cancer Center Clara Campal (CIOCCA) has closed 2011, its fourth year of activity, with a balance “very positive” in the words of its director, Dr. Manuel Hidalgo, and that concrete an average of 2,300 new patients per year and 330 (approximately 15 percent) including clinical trials, one third of which has been in Phase I research, that is, early clinical studies conducted with novel drugs.
The results of Ciocca, both of medical care for patients and results in them, as at the research, strengthen the center’s oncology unit reference as nationally and internationally.
According to figures provided by Dr. Hidalgo, “the volume of patients seen in the CIOCCA has experienced growth rates well suited since the launch of the center in 2011 increasing 22 percent over the previous year, which meets the objectives set for the year just ended, and is now comparable to that of public hospitals as the Gregorio Maranon and La Paz. ”
Research activity
On the research input of the center, its director describes as “spectacular” the percentage of patients treated in clinical trials, “the level of the best American schools, which is already a clear and positive contribution, first in terms of good Treatment of these patients, and secondly, in terms of our contribution to scientific progress. ”
Approximately one third of the 330 patients, ie 120, they have done in Phase I studies, “CIOCCA being the only center of Madrid, public or private, with a consolidated program of experimental therapy,” added Dr. Hidalgo, stressing that the center is, near the Hospital Vall d’Hebron (Barcelona), the only nationally and clearly as a reference center and at European level in a type of research, Phase I, which does not directly exists in the Spanish public health. ”
Objectives for 2012
For this year 2012 CIOCCA forecasts suggest even higher and, following the progression of growth that has registered so far, includes the objective of serving 2,500 patients new to the center and try to 400 in clinical trials, 20 percent in 2011. This director has his key allies as “a very good portfolio of studies for this year and unquestioned support of the pharmaceutical industry, required for Phase I trials.”
“Our portfolio highlights some studies, as, surely, the new version bevacizumab, the onset of viral therapy trials and oncolytic viruses, and deepening of an even more intense in our program of personalized medicine,” he adds.
One of the key considerations in dealing with cancer is to provide highly personalized treatments based on the molecular profiles of each tumor to address a challenge of the CIOCCA Oncology also shares and which will further work, for which it is need for new molecules.
“We have a pretty good collection of molecules, and a very important support for this in the pharmaceutical industry, especially foreign, has chosen our center for conducting research with innovative molecules, as evidenced by the fact that some companies large pharmaceutical and consolidated entrusted to CIOCCA molecules in its first foray outside the United States for the development of Phase I clinical trials, “he concludes.
Data in Oncology
Meanwhile, the Unit of Hematology and Oncology (UHOP) HM Hospitals, dependent and located in HM CIOCCA MonteprÃncipe University, has continued in its fifth year of operation on an upward trend, both in dealing with patients as Hematology Pediatric Oncology.
According to data provided by Dr. Blanca Lopez-Ibor, director of the service, which will cater for children up to age 19 years of a multidisciplinary, covering health and psychosocial area in 2011 “in 2011 unit 168 new patients attended (20 per cent of Oncology) and 1574 review consultations and 833 administered chemotherapy treatments. ”
As for hospital admissions last year amounted to 433, with an average stay of 4.78 days (90 per cent of oncological), while the treatments in the Day Hospital was 902, she adds , indicating also that the unit has carried out seven transplants of bone marrow and two treatments with I-131 MIBG (metaiodobenzylguanidine labeled with I-131) in coordination with the Nuclear Medicine Department Ciocca, the center also have undergone radiation therapy to twelve pediatric patients.
